DSFIR logo

DSM-Firmenich AG Stock Price

ENXTAM:DSFIR Community·€19.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 59 Fair Values set on narratives written by author

DSFIR Share Price Performance

€79.98
-10.28 (-11.39%)
€79.37
Fair Value
€79.98
-10.28 (-11.39%)
0.8% overvalued intrinsic discount
€79.37
Fair Value
Price €79.98
AnalystConsensusTarget €79.37
AnalystHighTarget €98.68
AnalystLowTarget €60.56

DSFIR Community Narratives

·
Fair Value €79.37 0.8% overvalued intrinsic discount

DSFIR: Resilient Consumer Health Demand Will Drive Performance Amid Pricing Pressure

0users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
·
Fair Value €98.68 18.9% undervalued intrinsic discount

Sustainability And Precision Nutrition Will Fuel Global Market Expansion

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value €60.56 32.1% overvalued intrinsic discount

Regulatory And Merger Challenges Will Constrain Benefits But Spark Growth

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€60.56
32.1% overvalued intrinsic discount
Revenue
2.44% p.a.
Profit Margin
5.27%
Future PE
30.82x
Price in 2029
€72.13

Trending Discussion

Updated Narratives

DSFIR logo

DSFIR: Share Buyback And New Listing Plan Will Shape Future Re Rating

Fair Value: €79.37 0.8% overvalued intrinsic discount
28 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
DSFIR logo

DSFIR: Share Buyback And Dual Listing Will Support Re Rating

Fair Value: €98.68 18.9% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
DSFIR logo

DSFIR: Reset Profitability Expectations Will Pressure Future Margin Resilience

Fair Value: €60.56 32.1% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

1 Risk
2 Rewards

DSM-Firmenich AG Key Details

€9.0b

Revenue

€5.5b

Cost of Revenue

€3.5b

Gross Profit

€3.3b

Other Expenses

€274.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 30, 2026
1.11
39.07%
3.03%
26.1%
View Full Analysis

About DSFIR

Founded
1902
Employees
26873
CEO
Dimitri de Vreeze
WebsiteView website
www.dsm-firmenich.com

DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. DSM-Firmenich AG was founded in 1902 and is based in Kaiseraugst, Switzerland.

Recent DSFIR News & Updates

Narrative Update Jun 24

DSFIR: Share Buyback And New Listing Plan Will Shape Future Re Rating

The updated analyst price target for DSM-Firmenich now sits at €79.37, a marginal adjustment from €79.82. This reflects a blend of more cautious discounting and slightly revised assumptions on revenue growth, profitability, and future P/E as analysts react to recent mixed target changes across the Street.

Recent updates

No updates